Breathgreen Pharmaceutical’s Mometasone Furoate Monohydrate API Approved By NMPA
Mometasone Furoate Monohydrate (Registration No. Y20240000274) has received the NMPA’s Approval on March 6, 2026. It marks the addition of one more flagship product to our company's inhalation API series.
Note: The product name "Mometasone Furoate" actually refers to "Mometasone Furoate Monohydrate".
Mometasone Furoate Monohydrate is aglucocorticoid preparations with anti-inflammatory and anti-allergic activities. They reduce inflammatory mediators and attenuate the body’s responses to immune complexes and delayed-type hypersensitivity reactions. They are indicated for the prophylaxis and treatment of seasonal and perennial allergic rhinitis.
Manufactured by our company, Mometasone Furoate Monohydrate meets the process requirements of relevant powder for inhalation pharmaceutical products. Using coarse API that are crystallized from the final synthesized step as primary particle in large size, we manipulate the powder property as required from clients. Our proprietary GMP-compliant micronization technology better ensures the safety and efficacy of both generic and innovative formulations, providing enhanced support for pharmaceutical registration applications.
